Gonadotrophin hormone releasing analogues open new doors in cancer treatment.
- 31 October 1987
- Vol. 295 (6606) , 1084-1085
- https://doi.org/10.1136/bmj.295.6606.1084
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Orchiectomy versus Long‐acting D‐Trp‐6‐LHRH in Advanced Prostatic CancerBritish Journal of Urology, 1987
- Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survivalJournal of Steroid Biochemistry, 1985
- Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.BMJ, 1985
- Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.BMJ, 1984
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.BMJ, 1984
- Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.BMJ, 1983
- Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.BMJ, 1983
- TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1982
- PROTECTION FROM CYCLOPHOSPHAMIDE-INDUCED TESTICULAR DAMAGE WITH AN ANALOGUE OF GONADOTROPIN-RELEASING HORMONEThe Lancet, 1981